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Abstract
Background: Leucine-rich kinase 2 (LRRK2)-linked Parkinson’s disease (PD) is
clinically indistinguishable from idiopathic PD (IPD). A pleiotropic neu-
ropathology has been recognized but the majority of studies in LRRK2
p.G2019S patients reveal Lewy-type synucleinopathy as its principal histological
substrate. To date no in vivo biomarkers of synucleinopathy have been found
in LRRK2 mutation carriers. Objectives: We used real-time quaking-induced
conversion (RT-QuIC) technique to assess the presence of alpha-synuclein
(a-syn) aggregates in cerebrospinal fluid (CSF) of LRRK2 p.G2019S carriers.
Methods: CSF samples of 51 subjects were analyzed: 15 LRRK2 p.G2019S PD,
10 IPD, 16 LRRK2 p.G2019S nonmanifesting carriers (NMC) and 10 healthy
controls. The presence of parkinsonism and prodromal symptoms was assessed
in all study subjects. Results: Forty percent (n = 6) LRRK2-PD, and 18.8%
(n = 3) LRRK2-NMC had a positive a-syn RT-QuIC response. RT-QuIC
detected IPD with 90% sensitivity and 80% specificity. No clinical differences
were detected between LRRK2-PD patients with positive and negative RT-
QuIC. A positive RT-QuIC result in LRRK2-NMC occurred in a higher propor-
tion of subjects meeting the Movement Disorder Society research criteria for
prodromal PD. Interpretation: RT-QuIC detects a-syn aggregation in CSF in a
significant number of patients with LRRK2-PD, but less frequently than in IPD.
A small percentage of LRRK2-NMC tested also positive. If appropriately vali-
dated in long-term studies with large number of mutation carriers, and hope-
fully, postmortem or in vivo confirmation of histopathology, RT-QuIC could
contribute to the selection of candidates to receive disease modifying drugs, in
particular treatments targeting a-syn deposition.
Introduction
Pathogenic mutations in the leucine-rich repeat kinase 2
(LRRK2) gene are one of the most frequent causes of
inherited Parkinson’s disease (PD).1,2 Among the different
mutations in this gene, p.G2019S is the most frequently
found in the population worldwide accounting for 1% of
sporadic and 4% of familial PD patients.2 LRRK2-linked
PD (LRRK2-PD) presents with an autosomal-dominant
inheritance pattern with incomplete penetrance. The
cumulative risk of developing PD in LRRK2 p.G2019S
cases is age dependant and varies widely depending on
the studies, from 25% to 42.5% at age 80 years3,4 and
currently is not possible to identify which subjects will
develop the disease. The clinical picture of LRRK2-PD is
largely indistinguishable from that of idiopathic PD
(IPD).2,5 Aggregated alpha-synuclein (a-syn) in the form
of Lewy-type pathology6 in the nervous tissue, similar to
that encountered in IPD, has been reported to occur in a
majority of LRRK2-PD p.G2019S cases, but LRRK2-PD
can have a pleiotropic neuropathological substrate.6–11
Kalia and colleagues have suggested that the occurrence
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of nonmotor symptoms such as cognitive impairment/de-
mentia, and anxiety is related to an underlying Lewy-type
synucleinopathy (LTS) in LRRK2-PD p.G2019S cases,9
however, it is currently not possible to reliably identify
these cases in vivo.
Seeking for evidence of abnormal a-syn aggregation in
different body tissues and fluids of patients with sus-
pected synucleinopathy has been one of the main strate-
gies in PD biomarkers research during the last years.12–15
Recently, an assay to detect a-syn oligomers in cere-
brospinal fluid (CSF), the real-time quaking-induced con-
version (RT-QuIC) test, has proven to identify PD
patients with high sensitivity and specificity.16 This tech-
nique, previously used as a diagnostic tool in diseases
caused by prion proteins, is based on the capacity of mis-
folded a-syn to induce the aggregation of monomeric spe-
cies of a-syn.17,18 Fairfoul and colleagues demonstrated in
CSF of pathologically confirmed patients with Lewy body
disease a positivity of the test in 92% of cases, whereas
none of the controls were positive. A validation cohort of
clinically diagnosed PD subjects resulted in a sensitivity
of the test of 95% and a specificity of 100%. Shahnawaz
and colleagues have equally demonstrated high sensitivity
and specificity of a similar assay, based on aggregated
a-syn amplification in the CSF, for the detection of PD
subjects.19 In the study by Fairfoul et al. three subjects
with idiopathic rapid eye movement sleep behavior disor-
der (RBD), considered a prodromal stage of PD20 also
presented abnormal aggregation of a-syn in CSF, suggest-
ing that this test could be used as a marker of premotor
PD.
The objective of our study was to assess the presence of
a-syn aggregation in CSF of LRRK2 mutation carriers
using RT-QuIC. Detection of such aggregates could be
indicative of the presence of an ongoing synucleinopathy.
Patients with manifest LRRK2-PD and a positive test
could eventually be candidates to receive disease modify-
ing drugs, in particular treatments directed against a-syn.
In LRRK2 nonmanifesting carriers (NMC) the identifica-
tion of a-syn in CSF may possible identify subjects who
will develop the motor syndrome of PD.
Methods
Patient groups and clinical assessment
This study was carried out in the Neurology Service at
the Hospital Clinic of Barcelona, in collaboration with
the National CJD Research & Surveillance Unit in Wes-
tern General Hospital, University of Edinburgh. The local
ethics committee approved all clinical protocols and writ-
ten informed consent was obtained from all the partici-
pants prior to enrollment.
We analyzed 51 CSF samples from LRRK2-PD
(n = 15) and LRRK2-NMC (n = 16) carrying the
p.G2019S mutation, IPD (n = 10) and HC (n = 10). IPD
and LRRK2-PD subjects were identified and recruited in
the Movement Disorders Unit from the Hospital Clınic of
Barcelona and collaborating centres of the Barcelona
LRRK2 study group. LRRK2-NMC were identified among
the relatives of LRRK2-PD subjects. All LRRK2 mutation
carriers (n = 31) of our cohort belong to 21 different
families. None of the 15 LRRK2-PD cases are related.
Among the 16 LRRK2-NMC, eight subjects are relative to
six LRRK-PD, and eight subjects are not and belong to
six different families. Genetic analysis was performed as
previously described.21 DNA was extracted from periph-
eral blood following standard procedures. Genotyping of
the G2019S mutation was performed using the pre-
designed TaqMan assay C-63498123-10 SNP rs34637584
and the R1441G/C/H mutation using a commercial Taq-
Man assay. Genotyping was performed on a StepOnePlus
Real-time PCR System (Life Tech. Inc.). CSF samples of
10 HC subjects were obtained for comparative purposes
among subjects undergoing a surgical procedure in our
institution that required an epidural anesthesia.
All the participants of this study were comprehensively
assessed for demographic and clinical characteristics.
Patients with IPD and LRRK2-PD were diagnosed clini-
cally according to UK PD Society Brain Bank criteria22
and recruited between May 2012 and October 2017. At
the time of inclusion to the study, none of the LRRK2-
NMC and none of the healthy controls presented signs of
parkinsonism. The severity of parkinsonism was assessed
with the Movement Disorders Society (MDS) sponsored
revision of the Unified Parkinson’s Disease Rating Scale
part III (MDS-UPDRS-III),23 the Hoehn and Yahr (H&Y)
stage,24 and the Schwab and England scale (S&E)25 Non-
motor symptoms were assessed using the MDS-UPDRS
part I and specific validated questionnaires for each
symptom. For evaluation of depression the Geriatric
Depression Scale-1526 or the Beck Depression Inventory-
II27 were used; dysautonomic symptoms were evaluated
with the Scale for Autonomic Function (SCOPA-AUT)28;
olfaction was assessed using the Spanish version of the
University of Pennsylvania Smell Test (UPSIT).29 The
presence of RBD was based on the RBD screening ques-
tionnaire30 and the Epworth Sleepiness Scale31 was used
to evaluate somnolence.
All LRRK2-NMC consented to undergo a dopamine
transporter (DaT) SPECT (123I-ioflupane) in less than
30 days from the lumbar puncture. SPECT images were
acquired in a dual-headed gamma camera (E-Cam, Sie-
mens), 64 images/head, with a matrix of 64 9 64. SPECT
images were classified visually by the local nuclear medi-
cine team of the hospital nuclear medicine physicians as
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normal when a symmetric intense tracer uptake in stria-
tum both caudate nucleus and putamen was observed. If
a unilateral or bilateral reduction was observed in the stri-
atal tracer uptake, the DAT-SPECT was considered as
abnormal.32 We also calculated the likelihood ratio and
posttest probability for conversion to manifest PD for
each LRRK2-NMC, based on the MDS research criteria
for prodromal PD as described elsewhere.33,34 We
included the available risk markers (age, sex, genetic sta-
tus, and habits) and prodromal markers (subtle motor
and nonmotor symptoms with the previously published
cutoffs and DaT SPECT results) for each subject. LRRK2
carriers have been followed up prospectively and 12 of 16
NMC have undergone additional clinical evaluations dur-
ing 2018.
CSF collection and handling
CSF collection protocol has been described elsewhere.35
Briefly, all the participants underwent the lumbar punc-
ture after 8-hour fast. Lumbar puncture was performed
using 20 or 22G needle, after local anesthesia. CSF was
collected into siliconized polypropilene tubes. 15–20 mL
of CSF were collected at room temperature, centrifuged at
2000g for 10 min, then transferred to 1.5 mL precooled
siliconized polypropilene aliquot tubes and immediately
freezed on dry ice. The frozen aliquots were stored at
80°C, until March 2018, when thawed, aliquoted into
coded 0.5–1 mL siliconized polypropilene tubes, refrozen
and transferred on dry ice from Barcelona to the Univer-
sity of Edinburgh (Scotland, UK) for the study described
here.
Real-time quaking-induced aggregation for
alpha-synuclein
The CSF samples were analyzed and reported without
prior knowledge of the clinical diagnosis and genetic sta-
tus of the donor. The RT-QuIC reaction buffer (RB) was
composed of 100 mmol/L phosphate buffer (pH 8.2),
10 lmol/L Thioflavin T (ThT) and 0.1 mg/mL human
recombinant full-length (1–140aa) a-syn (Stratech, Cam-
bridge, UK). Each well of a black 96-well plate with a
clear bottom (Nalgene Nunc International, Fisher Scien-
tific Ltd, UK) contained 98, 90, or 85 lL RB (depending
on volume of seed added) and 37  3 mg of 0.5 mm zir-
conium/silica beads (Thistle Scientific Ltd, Glasgow, UK).
Reactions were seeded with 2 lL of working strength
brain homogenate, 15 lL of undiluted CSF to a final
reaction volume of 100 lL. The plates were sealed with a
plate sealer film (Fisher Scientific Ltd, UK) and incubated
in a BMG OPTIMA FluoSTAR plate reader at 30°C for
120 h with intermittent shaking cycles: double orbital
with 1 min shake (200 rpm), 14 min rest. ThT fluores-
cence measurements (450 nm excitation and 480 nm
emission) were taken every 15 min. Each sample was run
in duplicate. A positive response was defined as a relative
fluorescence unit (rfu) value of >2SD above the mean of
the negative controls at 120 h in both of the CSF dupli-
cates. If only one of two CSF sample replicates gave a
positive response, the RT-QuIC analysis of the CSF sam-
ples was repeated in quadruplicate. A positive response in
two or more of the replicates was considered positive. If
only one of the replicates was positive, the RT-QuIC was
considered to be negative. The final fluorescence value
was the mean fluorescence value taken at 120 h. The
maximal fluorescence value was the highest mean fluores-
cent value seen during the a-syn RT-QuIC analytical run
of 120 h. A measure of the lag-phase was taken to be the
time it took to get to 50% aggregation as measured by a
rfu value of 44,000.
Statistical analysis
Qualitative variables were described by absolute and rela-
tive frequencies (%) and analyzed by the Fisher exact test.
Quantitative variables were described by median and
interquartile range (25th and 75th percentiles) and ana-
lyzed using the Kruskal–Wallis test for overall compar-
isons and the Mann–Whitney U test for pairwise
comparisons.
Results
Compared to IPD, LRRK2-PD subjects were younger (55
[48–64] years vs. 63.5 [57.5–70] years; P = 0.007), age at
onset of motor symptoms was earlier (49 [44–57] years
vs. 57.5 [50–62]; P = 0.03) and disease duration was
shorter (5 [3–6] vs. 8 [5.5–8]; P = 0.01). There were no
differences in the motor features, nonmotor symptoms or
disease severity between LRRK2-PD and IPD. The
LRRK2-NMC group was younger than the control group
(51.5 [38.5–64] vs. 68.5 [59.5–72.2]; P = 0.01).
After decoding the CSF samples, the results showed
that nine of 10 subjects in the IPD group and two of 10
in the control group were positive for RT-QuIC reaction,
obtaining a sensitivity of the test of a 90%, and a speci-
ficity of 80%. Six of 15 LRRK2-PD subjects had positive
results resulting in a sensitivity of 40% and three of 16
LRRK2-NMC (18.8%) also tested positive (Table 1). Of
the six LRRK2 patients that were positive, three had lag-
phases and final fluorescence values that were indistin-
guishable from the majority of the IPD group with the
remaining three patients having lag-phases that were
longer and final fluorescence value that were less than the
majority of the IPD group (Fig. 1). None of the LRRK2
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mutation carriers with a positive RT-QuIC result were
related. Two of the three LRRK2-NMC with a positive
RT-QuIC had LRRK2-PD relatives with a negative RT-
QuIC result.
The medical records of the IPD subject with a negative
result were subsequently reviewed. This subject’s motor
symptoms started at the age of 50 years, with asymmetric
rest tremor and bradykinesia. However, he has atypical
features like poor levodopa response, absence of motor
fluctuations or levodopa-induced dyskinesias, and devel-
opment of prominent lateralized trunkal dystonia (Pisa
syndrome). He has bilaterally reduced striatal DaT bind-
ing and a normal brain magnetic resonance. One of the
two control subjects with positive RT-QuIC reaction has
developed an action tremor of the hands and was diag-
nosed of having an action tremor of unknown cause
2 years after his participation in the study, and presents
now with cognitive complains. The rest of control sub-
jects have not developed symptoms or signs suggestive of
a neurodegenerative disease.
No statistically significant differences were observed
on MDS-UPDRS part I, II, and III scores, H&Y stage,
S&E and UPSIT scores between LRRK2-PD with positive
or negative RT-QuIC tests (Table 2) and LRRK2-NMC
with positive and negative RT-QuIC result (Table 3).
Two LRRK2-NMC, both with a negative RT-QuIC
result, reported to have vivid dreams and mobilization
while sleeping, but no video-polisomnography was per-
formed. Five of the 16 LRRK2-NMC had abnormal
UPSIT scores after adjusting for age and gender; of these
two had positive and three negative RT-QuIC results.
Two of three subjects with positive RT-QuIC result
(66.7%) had an abnormal DaT-SPECT, whereas only
two of 13 (15.4%) who were negative had altered striatal
DaT binding (Table 3). Three NMC, all with an altered
DaT SPECT met MDS criteria for probable prodromal
PD (>80% of threshold); two had positive a-syn RT-
QuIC result.
Twelve of 16 LRRK2-NMC, including the three positive
RT-QuiC cases, were clinically re-evaluated during 2018,
after a mean of 36.2 months (s = 21.6 months) of follow-
up, and none of them has motor symptoms suggestive of
clinical PD. Only one LRRK2-NMC has mild bradykinesia
on the evaluation after 31 months. This subject has nega-
tive RT-QuIC, but an abnormal nigrostriatal function on
the DaT-SPECT at the time of CSF collection, and meets
the criteria for probable prodromal PD.
Discussion
Our study confirms that a-syn aggregation in CSF using
RTQuIC identifies IPD with high specificity (90%) and
sensitivity (80%). Positive a-syn aggregation in the CSF
occurred in a significant number of patients with LRRK2-
PD p.G2019S but less frequently than in patients with
IPD.
Based on our results in IPD and previously published
data referred above16 it seems safe to presume that our
LRRK2-PD subjects with a positive RTQuIC result have
an underlying LTS. The percentage of positive subjects
among the LRRK2-PD group is lower than in IPD and
lower than expected since a majority of LRRK2 p.G2019S
cases are thought to have LTS.6 This lower percentage of
positive RT-QuIC in the LRRK2 cases could reflect the
reported neuropathological variability in LRRK2-PD
p.G2019S. RT-QuIC negative cases may not have LTS but
an alternative neuropathological substrate. Nonspecific
degeneration of the substantia nigra without abnormal
protein deposits has been described in LRRK2-PD
p.G2019S and still in other cases ubiquitin or tau inclu-
sions constitute the only abnormality.36–39 Studies with
larger cohorts of prospective brains of LRRK2 mutation
carriers have not been performed and the current
assumption that the majority of LRRK2 p.G2019S have a
synucleinopathy is based on limited case reports and
screens from LB specimens in brain banks,8 being possibly
confounded by a selection bias.
It is also possible that CSF a-syn seeds in LRRK2-PD
patients differ from those with IPD in their potency to
induce fibril formation and this could be altering the
RT-QuIC result. In our LRRK2-PD cases with a posi-
tive RT-QuIC, three subjects had longer lag-time phases
and lesser final fluorescence values compared to IPD
(Fig. 1) supporting this hypothesis. Mamais et al.40 have
shown distinct biochemical properties of aggregated a-
syn in LRRK2-PD p.G2019S compared to IPD, detect-
ing a lower percentage of highly insoluble a-syn species
Table 1. Prevalence of CSF positive a-syn RT-QuIC test, lag-phase
and final fluorescence values in IPD, LRRK2-PD, LRRK2-NMC, and
healthy controls.
Subject group (n)
Positive
RT-QuIC
[% (n)]
Lag-phase in
positive
RT-QuIC
(hours)2
Final fluorescence
in positive RT-QuIC
(rfu1)2
IPD (10) 90 (9) 132  20 60955  7685
LRRK2-PD (15) 40 (6) 151  33 50402  13862
LRRK2-NMC (16) 18.8 (3) 125  51 41228  21852
HC (10) 20 (2) 120  40 49016  17578
CSF, cerebrospinal fluid. IPD, idiopathic Parkinson’s disease. LRRK2-
PD, Leucine-rich repeat kinase 2 Parkinson’s disease; LRRK2-NMC,
Leucine-rich repeat kinase 2 nonmanifesting carriers; HC, Healthy
controls.
1rfu, relative fluorescence unit.
2Mean  SD.
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Figure 1. Final fluorescence values (A) and Lag-phase (B) of positive a-syn RT-QuIC subjects in IPD, LRRK2-PD, LRRK2-NMC and healthy controls
(HC). All but two of the IPD patients with positive RT-QuIC had final fluorescence values of 65,000, with the remaining two patients having
values of 54,801 and 45,792, respectively. The seven IPD that had final fluorescent values of 65,000 are represented by a single point on
Figure 1A. Among the LRRK2-PD patients with positive RT-QuIC two patients had a final fluorescence value of 65000 and appear as a single
point on Figure 1A. One LRRK2-PD patient and one LRRK2-NMC with positive RT-QuIC had unmeasurable lag-phases as the final fluorescence
values were less than 44,000 in both duplicates and are not represented in Figure 1B.
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in LRRK2-PD brain homogenates. Diversity in the
structure and self-aggregation potency of a-syn could
contribute to variability in RT-QuIC quantification and
even account for a negative result in some cases.
Another possible explanation for a negative test in the
presence of LTS could be that the negative LRRK2-PD
cases presented less a-syn burden, insufficient to induce
significant aggregation. So far, though, the studied
LRRK2-PD brains with LTS follow the staging scheme
of Braak,41 and in studies comparing LRRK2-PD to
IPD histopathology no differences in Lewy body and
neurite distribution have been observed.40
Table 2. Nonmotor symptoms of LRRK2 Parkinson’s disease patients.
Sex
Positive RT-QuIC Negative RT-QuIC
M M M M M M F F M F F F F M F
Age 51 38 51 59 50 64 45 44 55 68 68 57 48 64 60
Cognitive impairment1 1 0 1 0 0 1 1 0 0 1 0 0 0 0 0
Depression1 2 0 1 0 3 1 4 0 0 0 0 0 0 1 1
Urinary problems1 0 0 0 1 1 1 0 0 0 1 0 0 0 0 0
Constipation problems1 2 0 1 0 0 1 2 0 0 0 1 0 1 0 3
REM sleep behavior disorder2 No No No No No Yes No No No No No No Yes No No
Hyposmia3 Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes No Yes
MDS, International Parkinson’s disease and Movement Disorders Society.
1International Parkinson’s disease and Movement Disorders Society Unified Parkinson’s Disease Rating Scale part I scores: 0 = normal; 1 = slight,
2 = mild, 3 = moderate, 4 = severe (Goetz et al. 2008).
2Based on the REM sleep behavior questionnaire (Stiasny-Kolster et al. 2007).
3Based on the University of Pennsylvania Smell Test normative values (Doty et al. 1995).
Table 3. Clinical characteristics and MDS prodromal criteria likelihood ratio of LRRK2 nonmanifesting carriers.
Sex
Positive RT-QuIC Negative RT-QuIC
M F M M M M F M M F M M F F M M
Age 64 47 52 40 64 38 61 27 71 60 28 37 43 51 68 72
Cognitive
impairment1 0 2 0 0 0 0 0 0 0 0 0 0 0 1 0 0
Depression1 0 1 0 1 0 0 0 0 0 0 0 0 0 1 0 0
Bladder
symptoms1 0 0 1 0 0 0 0 0 0 0 0 0 0 0 0 0
Constipation1 0 1 0 0 0 0 0 0 0 0 0 0 0 0 1 0
RBD2 No No No No No No No No No No No No No Yes Yes No
Hyposmia3 Yes No Yes No No No No Yes No Yes No No No No Yes No
Abnormal
DaT-SPECT
Yes No Yes Yes No No No No Yes No No No No No No No
Meets criteria
for prodromal
PD*
Yes No Yes No No No No No Yes No No No No No No No
LR for probable
prodromal
PD PD†
947.6 2.9 1076.8 127.3 2.3 2.9 1.3 29.5 289.3 16.2 0.74 0.74 9.2 5.42 174.7 5.2
RBD, REM sleep behavior disorder; MDS, International Parkinson’s disease and Movement Disorders Society; PD, Parkinson’s disease; LR, likelihood
ratio.
1International Parkinson’s disease and Movement Disorders Society Unified Parkinson’s Disease Rating Scale part I scores: 0 = normal; 1 = slight,
2 = mild, 3 = moderate, 4 = severe (Goetz et al. 2008).
2Based on the REM sleep behavior questionnaire (Stiasny-Kolster et al. 2007).
3Based on the University of Pennsylvania Smell Test normative values (Doty et al. 1995).
*The subject meets the probability threshold of >80% for probable prodromal PD based on the MDS research criteria for prodromal PD (Berg
et al. 2015, Mirelman et al. 2018).
†Total likelihood ratio based on the MDS Research Criteria for prodromal PD (Berg et al. 2015, Mirelman et al. 2018). Missing values were not
imputed (LR = 1).
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In LRRK2-NMC RT-QuIC CSF positivity occurred in
three of the 15 (18.8%) subjects suggesting an ongoing
synucleinopathy in these cases. Two LRRK2-NMC with a
positive result had a relative with manifest LRRK-PD who
had a negative RT-QuIC result. Variable neuropathologi-
cal substrates, even in the same kindreds as has been well
documented to occur in cases with other pathogenic
LRRK2 mutations,42 could explain this finding. A decline
in DaT-SPECT (123I-ioflupane) binding has been previ-
ously suggested to be a useful tool to predict phenocon-
version in LRRK2-NMC.43 In our study two of three
(66.7%) LRRK2-NMC with a positive RTQuIC had an
abnormal DaT-SPECT result, whereas this occurred only
in two of 13 (15.3%) of the negative ones. The greater
frequency of altered DaT-SPECT uptake among the
RTQuIC-positive cases is in line with the interpretation
that these asymptomatic carriers are possibly those that
will eventually evolve into manifest PD. The higher pro-
portion of probable prodromal PD based on the MDS
prodromal criteria33,34 in those subjects with a positive
RTQuIC reaction, also supports this hypothesis.
We found a positive RT-QuIC test in two healthy con-
trols. One of these individuals has developed an action
tremor of the hands since the time of CSF acquisition
and may be harboring a neurodegenerative disorder. The
presence of phosphorylated a-syn aggregates in the ner-
vous system is not exceptional in living individuals with-
out neurological diseases.44–46 These cases may not
represent false-positive cases but rather possibly be cases
of incidental Lewy body disease. Postmortem studies in
the brain show LTS in about 15–20% of elder population
without parkinsonism or dementia during life.22,47,48
A major caveat of our study is the lack of neuropatho-
logical studies to establish a correlation between RT-QuIC
result and histological diagnosis. An additional limitation
of our study is the small number of subjects studied, pre-
cluding generalization of the results. Still the good sensi-
tivity and specificity found in the IPD group, practically
identical to those encountered by others using similar
techniques16,19 supports the validity of our data. Further
RT-QuIC studies with greater number of LRRK2 muta-
tion carriers, sufficient longitudinal follow-up to assess
phenoconversion in the asymptomatic carriers and, even-
tually, postmortem or in vivo49 studies to define the type
of pathological lesions occurring in these subjects will be
needed to validate our observation.
In conclusion, our results show that RT-QuIC method-
ology detects a-syn aggregation in CSF in a significant
number of patients with LRRK2-PD p.G2019S but less
frequently than in patient with IPD. In our cohort of
LRRK2-NMC, almost 20% of subjects were positive for
RT-QuIC suggesting that a positive test in LRRK2-NMC
may possibly identify those at major risk to eventually
develop parkinsonism. The high sensitivity and speci-
ficity of the results in IPD patients in this and previous
studies support the notion that the presence of a-syn
aggregation in CSF detected by RT-QuIC or similar a-
syn amplification methods, if appropriately validated,
could contribute to the selection of candidates to receive
disease modifying drugs, particularly treatments targeting
a-syn deposition.
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